



Developing anti-cancer drugs: our mission, our work and our passion.

Ecrins Therapeutics

Privately-held clinical stage biotech company



Pipeline

Stage of development

Asset / Indication

Target

Discovery


ADMET

Phase I/IIa

Exit/use strategy

ET-D5
Human oncology
Sarcomas (gateway)
Other solid tumors

PP1



Major value-creation step
for ET-D5
Go/NoGo (2023)
after completion of Phase IIa

Small molecule,
oncology

first-in-class,
undisclosed



Therapeutic mAb,
oncology

first-in-class,
undisclosed



Small molecule,
myopathies

first-in-class,
undisclosed




Patent expected in 2022

Patent expected in 2022

Patent expected in 2022

Pre-IND application (June 2019) – “no major issues”
Investigator’s brochure ready
Clinical protocol ready


Lead product ET-D5: first-in-class PP1 inhibitor developed for the treatment of sarcomas



- *In vitro*, ET-D5 is 3000x more potent than doxorubicine, gold standard for the treatment of sarcomas .
- *In vivo*, ET-D5 is active in dogs suffering from spontaneous STS.


Stage of development	
CMC, Formulation, Toxicology, Safety	✓
IND, Briefing Package, Investigator's Brochure, Clinical Protocol	✓
Pre-IND meeting application (April 2019)	✓
Written responses from the FDA – positive answers (June 2019)	✓
IND submission	Q3, 2020
Phase I start	Q4, 2020

ET-D5 program is at the door of the first-in-human clinical trial of Phase I/IIa




Sarcoma drugs market size

Epidemiology of sarcomas in the US (2017)



All sarcomas



■ Soft tissue sarcomas ■ Osteosarcomas

- The global sarcoma drugs market size will reach 1.2 bn in 2023 (CAGR of 8.5% in 2018-2023) – Grand View Research, Inc.
- Olaratumab was granted by FDA accelerated approval in Oct 2016 for STS. Before losing market authorization in Jan 2019, olaratumab generated close to 1 bn in sales for this indication.
- Subject to positive results of Phase IIa (2023) Ecrins Therapeutics will apply for the accelerated approval of ET-D5 for the treatment of soft-tissue sarcomas and osteosarcomas (expected revenue 300-400 m€ per year).

What we are looking for

Funding and/or development partners

Andrei Popov, MD, PhD

CEO Ecrins Therapeutics, SAS
BIOPOLIS, 5 av. du Grand Sablon
38700 La Tronche (Grenoble area) FRANCE
Tel.: +33 (0) 4 76 54 95 66
Cell: +33 (0) 6 50 63 34 04
Fax: +33 (0) 4 76 54 95 68
andrei.popov@ecrins-therapeutics.com

